Adial Pharmaceuticals, INC 10-Q quarterly reports

Adial Pharmaceuticals reports a net loss of $2.0 million for Q1 2026 while continuing development of its AD04 addiction treatment candidate.

Adial Pharmaceuticals reports reduced net losses but raises substantial doubt about its ability to continue as a going concern, with cash only sufficient into Q2 2026, while navigating Nasdaq listing compliance issues.

Adial Pharmaceuticals reported reduced net losses and a significant increase in cash for Q2 2025, driven by recent capital raises, but faces ongoing going concern doubts and Nasdaq listing challenges.

Adial Pharmaceuticals reports a net loss for Q1 2025, focusing on AD04 development and securing additional funding through a warrant inducement agreement.

Adial Pharmaceuticals' Q3 2024 report reveals a significant increase in research and development expenses, alongside ongoing efforts to secure additional funding for its operations.

Adial Pharmaceuticals experienced a net loss of $2.46 million in the second quarter of 2024, driven by increased research and development expenses.

Adial Pharmaceuticals reports a net loss of $6.5 million for Q1 2024, while highlighting progress in AD04 development and recent financing activities.